Intrexon | XON - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Agenus USD -10.61M 263.52M 2025-12
Alaunos Therapeutics USD -7.84M 633K 2023-12
Amgen USD 1.51B 2.41B 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 343.6M 46.34M 2026-03
Intrexon USD -60.48M 27.09M 2024-06
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
MannKind USD -16.37M 4.56M 2026-03
Merck USD 3.42B 3.32B 2025-12
Novartis USD 3.84B 802M 2026-03
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Thermo Fisher Scientific USD 2.12B 295M 2025-12
Veracyte USD 29.97M 10.66M 2026-03
Xencor USD -128.64M 124.37M 2026-03